Evaluation of the relationship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population

Infection, Genetics and Evolution

Volumn 21, Issue , 2014, Pages 8-14

  Jin, Guojiang ^a   Kang, Hui ^a   Chen, Xin ^a   Dai, Di ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis C virus (HCV); High resolution melt (HRM); IL10RB; IL28B; IL28RA; Polymorphism

Indexed keywords

GENOMIC DNA; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 28B; CYTOKINE RECEPTOR; IFNLR1 PROTEIN, HUMAN; IL10RB PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; CHINESE HAN; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; IL10RB GENE; IL28B GENE; IL28RA GENE; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; GENETIC PREDISPOSITION; GENETICS; HEPACIVIRUS; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-10 RECEPTOR BETA SUBUNIT; INTERLEUKINS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CYTOKINE; RISK FACTORS;

EID: 84887538459     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2013.10.009     Document Type: Article

References (27)

1. Ank N., West H., Paludan S.R. IFN-lambda: novel antiviral cytokines. J. Interferon. Cytokine. Res. 2006, 26:373-379.
2. Chae S.C., Park Y.R., Li C.S., Lee J.H., Yang Y.S., Zhang Q., Kim K.S., Chung H.T. Analysis of the variations in IL-28RA gene and their association with allergic rhinitis. Exp. Mol. Med. 2006, 38:302-309.
3. Cui Q., Zhang Y.X., Su J., Chen X., Ding K., Lei N., Liu Y., Li J., Zhang Y., Yu R.B. Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infect. Genet. Evol. 2011, 11(7):1682-1689.
4. Fischer J., Böhm S., Scholz M., Müller T., Witt H., George J., Sarrazin C., Susser S., Schott E., Suppiah V., Booth D.R., Stewart G.J., van Bömmel F., Brodzinski A., Fülöp B., Migaud P., Berg T. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology. 2012, 55(6):1700-1710.
5. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
6. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009, 461:399-401.
7. Glocker E.O., Kotlarz D., Boztug K., Gertz E.M., Schäffer A.A., Noyan F., Perro M., Diestelhorst J., Allroth A., Murugan D., Hätscher N., Pfeifer D., Sykora K.W., Sauer M., Kreipe H., Lacher M., Nustede R., Woellner C., Baumann U., Salzer U., Koletzko S., Shah N., Segal A.W., Sauerbrey A., Buderus S., Snapper S.B., Grimbacher B., Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N.Engl. J. Med. 2009, 361(21):2033-2045.
8. Gong Q.M., Kong X.F., Yang Z.T., Xu J., Wang L., Li X.H., Jin G.D., Gao J., Zhang D.H., Jiang J.H., Lu Z.M., Zhang X.X. Association study of IFNAR2 and IL10RB genes with the susceptibility and interferon response in HBV infection. J. Viral. Hepat. 2009, 16:674-680.
9. Honda M., Sakai A., Yamashita T., Nakamoto Y., Mizukoshi E., Sakai Y., Yamashita T., Nakamura M., Shirasaki T., Horimoto K., Tanaka Y., Tokunaga K., Mizokami M., Kaneko S. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010, 139:499-509.
10. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., Donnelly R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4:69-77.
11. Lopez de Lapuente A., Alloza I., Goertsches R., Zettl U.K., Urcelay E., Arroyo R., Comabella M., Montalban X., Antigüedad A., Vandenbroeck K. Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. J. Neuroimmunol. 2012, 245(1-2):98-101.
12. Maekawa S., Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J. Gastroenterol. 2009, 44:1009-1015.
13. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R., Rice C.M. Interferons inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006, 131:1887-1898.
14. Miller D.M., Klucher K.M., Freeman J.A., Hausman D.F., Fontana D., Williams D.E. Interferon lambda as a potential new therapeutic for hepatitis C. Ann. N. Y. Acad. Sci. 2009, 1182:80-87.
15. Muir A.J., Shiffman M.L., Zaman A., Yoffe B., de la Torre A., Flamm S., Gordon S.C., Marotta P., Vierling J.M., Lopez-Talavera J.C., Byrnes-Blake K., Fontana D., Freeman J., Gray T., Hausman D., Hunder N.N., Lawitz E. Phase 1b study of pegylated interferon-lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010, 52:822-832.
16. Ramos E.L. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J. Interferon. Cytokine. Res. 2010, 30:591-595.
17. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Günthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Müllhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345.
18. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., McKnight G., Clegg C., Foster D., Klucher K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63-68.
19. Shi X., Pan Y., Wang M., Wang D., Li W., Jiang T., Zhang P., Chi X., Jiang Y., Gao Y., Zhong J., Sun B., Xu D., Jiang J., Niu J. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS. One. 2012, 7(5):e37054.
20. Smith K.R., Suppiah V., O'Connor K., Berg T., Weltman M., Abate M.L., Spengler U., Bassendine M., Matthews G., Irving W.L., Powell E., Riordan S., Ahlenstiel G., Stewart G.J., Bahlo M., George J., Booth D.R. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome. Med. 2011, 3(8):57.
21. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Müller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
22. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
23. Thio C.L. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin. Liver. Dis. 2008, 12:713-726.
24. Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., Nolt K., Nelson K.E., Strathdee S.A., Johnson L., Laeyendecker O., Boitnott J., Wilson L.E., Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000, 284:450-456.
25. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009, 461:798-801.
26. Urban T.J., Thompson A.J., Bradrick S.S., Fellay J., Schuppan D., Cronin K.D., Hong L., McKenzie A., Patel K., Shianna K.V., McHutchison J.G., Goldstein D.B., Afdhal N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010, 52(6):1888-1896.
27. Zhou Z., Hamming O.J., Ank N., Paludan S.R., Nielsen A.L., Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells though signaling pathways involving both Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 2007, 81:7749-7758.